At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 771 enrolled
Drug / intervention
Telavancin +1 moredrug
Likely dose
Telavancin 10 mg/kg/day IV for up to 21 days; Vancomycin 1 g IV every 12 hours for up to 21 daysAI-extracted
Key inclusion· 2
- ✓Clinical signs and symptoms of pneumonia acquired after ≥48 hours of continuous stay in inpatient acute or chronic care facility
- ✓Pneumonia acquired within 7 days after discharge from hospitalization of ≥3 days duration
Key exclusion· 1
- ✕Received >24 hours of potentially effective systemic (IV, IM, or PO) antibiotic therapy for Gram-positive pneumonia immediately prior to randomization
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus
In Brief
A Phase 3 clinical trial evaluating Telavancin and Vancomycin for Bacterial Pneumonia. Completed, enrolled 771 participants across 1 site.
Detailed Summary
Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Pneumonia
CountriesIsrael
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2005
First PostedJul 2005
Primary CompletionMay 2007
TodayJul 2026
First PostedJul 26, 2005
Enrollment StartJan 1, 2005
Primary CompletionMay 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.9 years ago
Interventions
Telavancindrug
Telavancin 10 mg/kg/day IV for up to 21 days
Vancomycindrug
Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days